• "HTG technology allowed us to take our research further faster."

     

    Dr. Peter Ansell

    Scientific Director and Research Fellow

    Precision Medicine-Oncology

    AbbVie

     

    Read more

  • HTG Transcriptome Panel Available Now

    Simplify gene expression analysis with our new comprehensive human transcriptome panel.

    Learn More

 

Peter Ansell, Ph.D., Scientific Director and Research Fellow, Precision Medicine Oncology at AbbVie discussed how his team overcame many challenges they have previously faced using FFPE clinical samples by integrating HTG’s innovative HTG Transcriptome Panel (HTP) into their biomarker strategies.

Stream on-demand webinar

News & Events

San Antonio Breast Cancer Symposium 2022

December 6-10, 2022 | Come and see us in San Antonio, TX at the San Antonio Breast Cancer Symposium

December 6-10, 2022 | Come and see us in San Antonio, TX at the San Antonio Breast Cancer Symposium

Posted on:

Keep Reading

64th ASH Annual Meeting and Exposition

December 10-13, 2022 | Come and see us in New Orleans, LA at the 64th American Society of Hematology Annual meeting and Exposition

December 10-13, 2022 | Come and see us in New Orleans, LA at the 64th American Society of Hematology Annual meeting and Exposition

Posted on:

Keep Reading

The Festival of Genomics & Biodata 2023

January 25-26, 2023 | Come and see us in London at the 2023 Festival of Genomics

January 25-26, 2023 | Come and see us in London at the 2023 Festival of Genomics

Posted on:

Keep Reading

HTG Molecular Diagnostics Reports Third Quarter 2022 Results

TUCSON, Ariz. , Nov. 10, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today reported financial results for the…

Keep Reading

HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications

TUCSON, Ariz. and PARIS , Oct. 26, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, and OmiCure ® , a leading European digital health company that…

Keep Reading

HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery

TUCSON, Ariz. , Oct. 12, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, completed its planned milestones for the third quarter of 2022, further…

Keep Reading

Publications

Read white papers or journal publications and view other scientific content. 

Documents

Tech Notes

White Papers

Therapeutics

Posters

Abstracts

Peer Reviewed Publications

Editorials

Reviews


Careers at HTG

At HTG, we are always looking for talented individuals to help us deliver our next-generation sequencing-based products throughout the world.

New Careers

See All Careers


Page last updated November 04, 2022